Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.
Mamtani R, Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Sridhar S, Pappot H, Valderrama B, Gurney H, Bedke J, Van Der Heijden M, Wu C, Hepp Z, McKay C, Petrylak D. Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy. Journal Of Clinical Oncology 2021, 39: 4539-4539. DOI: 10.1200/jco.2021.39.15_suppl.4539.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaUrothelial carcinomaOpen-label phase 3 studyCompliance rateGlobal health status scaleRandomized phase 3 trialSymptom scales/itemsLife Questionnaire Core 30Median overall survivalQuestionnaire compliance ratesPhase 3 studyPhase 3 trialCancer Core QualityWeeks of treatmentHealth status scalesRisk of deathQLQ-C30 scoresQLQ-C30 domainsQuality of lifeBenefit/riskScales/itemsPain symptomsAppetite lossLiver metastasesOverall survival